BioBehavioral Diagnostics Company announced that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009. Calvin R. Sumner, M.D.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In addition, data regarding the pharmacokinetic profile of Daytrana in children and adolescents was also presented.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV™ (guanfacine) Extended Release Tablets, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists being held October 27 - November 1 in Honolulu.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr.
Schoolchildren with attention deficit/hyperactivity disorder are substantially more likely to engage in many types of criminal activity such as burglary, theft and drug dealing as they grow older, a new study by the Yale School of Public Health has found. The research was published in The Journal of Mental Health Policy and Economics.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr.
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
Can Excessive Video Game Playing Cause Attention Problems?
Yes, its just like you thought. The more your child or teen sits around watching TV or playing video games, the more at risk they will be for learning problems and attention problems. We have written about this before, and not to much has changed except that the research is starting to show up to validate what parents have known for five years now. Read more of the article...
KemPharm, Inc. announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.
Parents have long lectured their children about the mind-numbing effects of playing video games all day. And a new Iowa State University study has found that high volume action video game players -- those who play around 40 hours per week -- actually had more difficulty keeping focused on tasks requiring longer, more proactive attention than those who played video games less than a couple of hours a week.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.
Rats exposed to high doses of amphetamines at an age that corresponds to the later years of human adolescence display significant memory deficits as adults - long after the exposure ends, researchers report. The declines in short-term or "working" memory are most pronounced when the rats are exposed during adolescence, rather than as adults, the researchers found.
Video game players are often accused of passively reacting to tasks that are spoon fed to them through graphics and stimuli on the screen. A group of researchers from Iowa State University shows that playing lots of video games has different effects on two types of cognitive activity, proactive and reactive attention. Proactive attention can be thought of as a sort of "gearing up" mechanism.